US FDA Gets Out Of The 'Competition' Business – At Least In Oncology

 
• By Michael McCaughan
competition
Did the FDA reveal a new policy when staff said competition would not be considered in the review of Lilly/Innovent’s sintilimab? • Source: Alamy

More from Product Reviews

More from Pink Sheet